Lymphoseek approved to help locate lymph nodes

March 13, 2013

(HealthDay)—The injected imaging drug Lymphoseek (technetium Tc 99m tilmanocept) has been approved by the U.S. Food and Drug Administration to help surgeons locate the lymph nodes among people with breast cancer or melanoma.

The lymph nodes filter lymphatic fluid that flows throughout the body. This fluid may contain if it has passed through diseased tissue, the FDA said in a news release. By surgically examining the lymph nodes, doctors may be able to conclude if cancer has spread.

Lymphoseek is an imaging drug that helps locate the lymph nodes, but it is not a drug, the agency stressed. It's the first lymph-node mapping drug to be approved by the FDA in 30 years.

The drug's safety and effectiveness were established in clinical trials involving 332 people with melanoma or breast cancer. The most common adverse reactions reported were pain and/or irritation at the injection site.

Lymphoseek is marketed by Navidea Biopharmaceuticals, based in Dublin, Ohio.

Explore further: Less invasive surgery detects residual breast cancer in lymph nodes after chemotherapy

More information: The FDA has more about this approval.

Related Stories

Less invasive surgery detects residual breast cancer in lymph nodes after chemotherapy

December 5, 2012
Most patients whose breast cancer has spread to their lymph nodes have most of the lymph nodes in their armpit area removed after chemotherapy to see if any cancer remains. A study conducted through the American College of ...

New signaling pathway linked to breast cancer metastasis

April 2, 2012
Lymph nodes help to fight off infections by producing immune cells and filtering foreign materials from the body, such as bacteria or cancer cells. Thus, one of the first places that cancer cells are found when they leave ...

Evidence strengthens link between NSAIDs and reduced cancer metastasis

February 13, 2012
A new study reveals key factors that promote the spread of cancer to lymph nodes and provides a mechanism that explains how a common over-the-counter anti-inflammatory medication can reduce the spread of tumor cells through ...

Recommended for you

CAR-T immunotherapy may help blood cancer patients who don't respond to standard treatments

October 20, 2017
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is one of the first centers nationwide to offer a new immunotherapy that targets certain blood cancers. Newly approved ...

Researchers pinpoint causes for spike in breast cancer genetic testing

October 20, 2017
A sharp rise in the number of women seeking BRCA genetic testing to evaluate their risk of developing breast cancer was driven by multiple factors, including celebrity endorsement, according to researchers at the University ...

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.